|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death显示文摘 | Jiang H Gomez-Manzano C Aoki H Alonso MM Kondo S McCormick F Xu J Kondo Y Bekele BN Colman H Lang FF Fueyo J | 2007 | 中国神经肿瘤杂志2007，5，3： | 24 |
| 2 | Outcome of patients with acute, necrotizing pancreatitis requiring drainage-does drainage size matter?显示文摘AIM:To assess the outcome of patients with acute necrotizing pancreatitis treated by percutaneous drainage with special focus on the influence of drainage size and number. METHODS:We performed a retrospective analysis of 80 patients with acute pancreatitis requiring percutaneous drainage therapy for infected necroses. Endpoints were mortality and length of hospital stay. The influence of drainage characteristics such as the median drainage size, the largest drainage size per patient and the total drainage plane per patient on patient outcome was evaluated. RESULTS:Total hospital survival was 66%. Thirty-four patients out of all 80 patients (43%) survived acute necrotizing pancreatitis with percutaneous drainage therapy only. Eighteen patients out of all 80 patients needed additional percutaneous necrosectomy (23%). Ten out of these patients required surgical necrosectomy in addition, 6 patients received open necrosectomy without prior percutaneous necrosectomy. Elective surgery was performed in 3 patients receiving cholecystectomy and one patient receiving resection of the parathyroid gland. The number of drainages ranged from one to fourteen per patient. The drainage diameter ranged from 8 French catheters to 24 French catheters. The median drainage size as well as the largest drainage size used per patient and the total drainage area used per patient did not show statistically significant influence on mortality. CONCLUSION:Percutaneous drainage therapy is an effective tool for treatment of necrotizing pancreatitis.Large bore drainages did not prove to be more effective in controlling the septic focus. | T Bruennler J Langgartner S Lang CE Wrede F Klebl S Zierhut S Siebig F Mandraka F Rockmann B Salzberger S Feuerbach J Schoelmerich OW Hamer | 2008 | World Journal of Gastroenterology2008，14，5： | 23 |
| 3 | Liver surgery in cirrhosis and portal hypertension显示文摘The prevalence of hepatic cirrhosis in Europe and the United States, currently 250 patients per 100000 inhabitants, is steadily increasing. Thus, we observe a significant increase in patients with cirrhosis and portal hypertension needing liver resections for primary ormetastatic lesions. However, extended liver resections in patients with underlying hepatic cirrhosis and portal hypertension still represent a medical challenge in regard to perioperative morbidity, surgical management and postoperative outcome. The Barcelona Clinic Liver Cancer classification recommends to restrict curative liver resections for hepatocellular carcinoma in cirrhotic patients to early tumor stages in patients with Child A cirrhosis not showing portal hypertension. However, during the last two decades, relevant improvements in preoperative diagnostic, perioperative hepatologic and intensive care management as well as in surgical techniques during hepatic resections have rendered even extended liver resections in higher-degree cirrhotic patients with portal hypertension possible. However, there are few standard indications for hepatic resections in cirrhotic patients and risk stratifications have to be performed in an interdisciplinary setting for each individual patient. We here review the indications, the preoperative risk-stratifications, the morbidity and the mortality of extended resections for primary and metastatic lesions in cirrhotic livers. Furthermore, we provide a review of literature on perioperative management in cirrhotic patients needing extrahepatic abdominal surgery and an overview of surgical options in the treatment of hepatic cirrhosis. | Christina Hackl Hans J Schlitt Philipp Renner Sven A Lang | 2016 | World Journal of Gastroenterology2016，22，9： | 21 |
| 4 | Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump显示文摘AIM: To study the association of three common ABCB11 and ABCC2 polymorphisms (ABCB11: 1331T>C V444A; ABCC2: 3563T>A V1188E and 4544G>A C1515Y) with intrahepatic cholestasis of pregnancy (ICP) and contraceptive-induced cholestasis (CIC). METHODS: ABCB11 and ABCC2 genotyping data were available from four CIC patients and from 42 and 33 ICP patients, respectively. Allele-frequencies of the studied polymorphisms were compared with those in healthy pregnant controls and Caucasian individuals. Furthermore, serum bile acid levels were correlated with the presence or absence of the 1331 C allele.RESULTS: The ABCB11 1331T>C polymorphism was significantly more frequent in cholestatic patients than in pregnant controls: C allele 76.2% (CI, 58.0-94.4) vs 51.3% (CI 35.8-66.7), respectively (P = 0.0007); and CC allele 57.1% (CI 36.0-78.3) vs 20% (CI 7.6-32.4), respectively (P = 0.0065). All four CIC patients were homozygous carriers of the C allele. In contrast, none of the studied ABCC2 polymorphism was overrepresented in ICP or CIC patients. Higher serum bile acid levels were found in carriers of the 1331CC genotype compared to carriers of the TT genotype.CONCLUSION: Our data support a role for the ABCB11 1331T>C polymorphism as a susceptibility factor for the ←←← development of estrogen-induced cholestasis, whereas no such association was found for ABCC2. Serum bile acid and γ-glutamyl transferase levels might help to distinguish ABCB4- and ABCB11-related forms of ICP and CIC. | Yvonne Meier Tina Zodan Carmen Lang Roland Zimmermann Gerd A Kullak-Ublick Peter J Meier Bruno Stieger Christiane Pauli-Magnus | 2008 | World Journal of Gastroenterology2008，14，1： | 20 |
| 5 | AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma显示文摘Intrahepatic cholangiocarcinomas (ICC) are neoplasms that originate from cholangiocytes and can occur at any level of the biliary tree. Surgical resection is the current therapy of choice for this highly aggressive cancer. However, the 5-year survival still is poor, with high recurrence rates. Due to the intrahepatic growth a signifi cant proportion of patients present with advanced disease and are not candidates for curative surgery or transplantation. The existing palliative options are of limited benefit and there is a great necessity for novel therapeutic options. In this article we review the role of the phosphoinositide 3-kinase(PI3K)/ AKT and extracellular regulated kinase (ERK) signaling pathways in ICC and present new data on the prognostic value of these protein kinases. Finally, we discuss future upcoming therapeutic options based on targeting these signaling pathways. | KJ Schmitz H Lang J Wohlschlaeger GC Sotiropoulos H Reis KW Schmid HA Baba | 2007 | World Journal of Gastroenterology2007，13，48： | 8 |
| 6 | Driving vascular endothelial cell fate of human multipotent Isl1 heart progenitors with VEGF modified mRNA显示文摘multipotent 心祖先的不同家庭在哺乳动物的 cardiogenesis 期间在多样的心脏的、光滑的肌肉和 endothelial 房间系的产生起一个中央作用。驾驶这些 multipotent 祖先的房间命运决定的精确 paracrine 信号的鉴定,和小说的开发来临在 vivo 交付这些信号,是向开他们的再生治疗学的潜力的关键步。此处,我们识别了位于早人的胎儿的心(OFT-ECs ) 的流出道的人的心脏的 endothelial 中介的一个家庭,由 Isl1 和 CD144/vWF 的 coexpression 描绘了。由比较人的 OFT-ECs 和非心脏的 EC 表示的 angiocrine 因素,脉管的 endothelial 生长因素( VEGF ) A 作为最富有地表示的因素被识别,并且同种细胞的试金记录了它的能力驱使人的胚胎的干细胞(转换字符)的 endothelial 说明以一种 VEGF 受体依赖者方式导出 Isl1 +祖先。人的 Isl1-ECs (区分开来与导出 hESC 的 ISL1 + 祖先的 endothelial 房间) 以心脏的 endothelial 祖先的表示类似于 OFT-ECs -- 并且 endocardial 房间特定的基因,证实他们的机关特性。决定是否 VEGF -- A 可能是服务一在里面为人的导出转换字符的 Isl1-ECs 的 vivo 房间命运开关,我们证实化学上使用的一条新奇途径作为一个平台修改了 mRNA 为短暂,还在心血管的祖先的 paracrine 因素的高度有效的表示。VEGF 的 Overexpression -- A 支持在 vivo 的人的 Isl1 + 祖先的不仅 endothelial 说明而且嫁接,增长和幸存(减少的 apoptosis ) 。从人的 pluripotent 干细胞的心脏特定的人的 Isl1-ECs 的大规模推导,结合了能力驾驶跟随移植的 endothelial 说明,嫁接,和幸存,在心为脉管的新生建议新奇策略。 | Kathy O Lui Llor Lang Eduardo A Silva Lei Bu Makoto Sahara Ronald A Li David J Mooney Kenneth R Chien | 2013 | Cell Research2013，23，10： | 6 |
| 7 | 早发急性心肌梗死的长期结局和风险评估:10年随访研究显示文摘早发急性心肌梗死(acute myocardial infarction,AMI)是一种罕见的疾病,发病率和死亡率很高。该文在再灌注治疗广泛应用的大环境下,纳入前瞻性研究人群进行早发AMI的预后研究。方法:这项前瞻性多中心研究中连续纳入102例AMI存活者(≤40岁),临床预后通过奥地利死亡登记处和维也纳集中患者管理系统进行查询。 | 刘莉 叶鹏 Winter MP Blessberger H Alimohammadi A Pavo N Huber K Wojta J Lang IM Wiesbauer F Goliasch G | 2017 | 中华高血压杂志2017，25，4： | 5 |
| 8 | Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions显示文摘AIM To quantify drug-drug-interactions(DDIs) encountered in patients prescribed hepatitis C virus(HCV) treatment, the interventions made, and the time spent in this process.METHODS As standard of care, a clinical pharmacist screened for DDIs in patients prescribed direct acting antiviral(DAA) HCV treatment between November 2013 and July 2015 at the University of Colorado Hepatology Clinic. HCV regimens prescribed included ledipasvir/sofosbuvir(LDV/SOF), paritaprevir/ritonavir/ombitasvir/dasabuvir(OBV/PTV/r + DSV), simeprevir/sofosbuvir (SIM/SOF), and sofosbuvir/ribavirin (SOF/RBV). This retrospective analysis reviewed the work completed by the clinical pharmacist in order to measure the aims identified for the study. The number and type of DDIs identified were summarized with descriptive statistics.RESULTS Six hundred and sixty four patients(83.4% Caucasian, 57% male, average 56.7 years old) were identified; 369 for LDV/SOF, 48 for OBV/PTV/r + DSV, 114 for SIM/SOF, and 133 for SOF/RBV. Fifty-one point five per cent of patients were cirrhotic. Overall, 5217 medications were reviewed (7.86 medications per patient) and 781 interactions identified (1.18 interactions per patient). The number of interactions were fewest for SOF/RBV (0.17 interactions per patient) and highest for OBV/PTV/r + DSV (2.48 interactions per patient). LDV/SOF and SIM/SOF had similar number of interactions (1.28 and 1.48 interactions per patient, respectively). Gastric acid modifiers and vitamin/herbal supplements commonly caused interactions with LDV/SOF. Hypertensive agents, analgesics, and psychiatric medications frequently caused interactions with OBV/PTV/r + DSV and SIM/SOF. To manage these interactions, the pharmacists most often recommended discontinuing the medication (28.9%), increasing monitoring for toxicities (24.1%), or separating administration times (18.2%). The pharmacist chart review for each patient usually took approximately 30 min, with additional time for more complex patients. CONCLUSION DDIs are common with HCV medications and management can require medication adjustments and increased monitoring. An interdisciplinary team including a clinical pharmacist can optimize patient care. | Jacob A Langness Matthew Nguyen Amanda Wieland Gregory T Everson Jennifer J Kiser | 2017 | World Journal of Gastroenterology2017，23，9： | 5 |
| 9 | Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial显示文摘 | Gunnar Folprecht Thomas Gruenberger Wolf O Bechstein Hans-Rudolf Raab Florian Lordick J?rg T Hartmann Hauke Lang Andrea Frilling Jan Stoehlmacher Jürgen Weitz Ralf Konopke Christian Stroszczynski Torsten Liersch Detlev Ockert Thomas Herrmann Eray Goekkurt | 2010 | Lancet Oncology2010，，1： | 3 |
| 10 | Early clinical worsening in patients with TIA or minor stroke: The Austrian Stroke Unit Registry显示文摘 | J Ferrari M Knoflach S Kiechl J Willeit S Schnabl L Seyfang W Lang | 2010 | Neurology2010，，2： | 2 |
| 11 | Mixture toxicity of nitrobenzene and trinitrobenzene using the marine bacterium Vibrio harveyl as the test organism显示文摘 | Thomulka K W Lange J H | 1997 | Ecotoxicity and Environmental Safety1997，36，2： | 2 |
| 12 | Therapy of organophosphate poisoning in the rat by direct effects of oximes unrelated to ChE-reactivation 显示文摘 | Van Helden HPM De Lange J Busker RW | 1991 | Arch Toxicol1991，65，： | 2 |
| 13 | Xanthogranulomatous cholecystitis resembling carcinoma with extensive tumorous infiltration of the liver and colon显示文摘 | Jürgen Pinocy Antje Lange Claudius K?nig Edwin Kaiserling Horst D. Becker Stefan M. Kr?ber | 2003 | Langenbeck’s Archives of Surgery2003，，1： | 2 |
| 14 | Gastroesophageal reflux disease after diagnostic endoscopy in the clinical setting显示文摘AIM: To investigate the outcome of patients with symptoms of gastroesophageal reflux disease (GERD) referred for endoscopy at 2 and 6 mo post endoscopy. METHODS: Consecutive patients referred for upper endoscopy for assessment of GERD symptoms at two large metropolitan hospitals were invited to participate in a 6-mo non-interventional (observational) study.The two institutions are situated in geographically and socially disparate areas. Data collection was by selfcompletion of questionnaires including the patient assessment of upper gastrointestinal disorders symptoms severity and from hospital records. Endoscopic finding using the Los-Angeles classification, symptom severity and it's clinically relevant improvement as change of at least 25%, therapy and socio-demographic factors were assessed. RESULTS: Baseline data were available for 266 patients and 2-mo and 6-mo follow-up data for 128 and 108 patients respectively. At baseline, 128 patients had erosive and 138 non-erosive reflux disease. Allmost all patient had proton pump inhibitor (PPI) therapy in the past. Overall, patients with non-erosive GERD at the index endoscopy had significantly more severe symptoms as compared to patients with erosive or even complicated GERD while there was no difference with regard to medication. After 2 and 6 mo there was a small, but statistically significant improvement in symptom severity (7.02 ± 5.5 vs 5.9 ± 5.4 and 5.5 ± 5.4 respectively); however, the majority of patients continued to have symptoms (i.e. , after 6 mo 81% with GERD symptoms). Advantaged socioeconomic status as well as being unemployed was associated with greater improvement. CONCLUSION: The majority of GORD patients receive PPI therapy before being referred for endoscopy even though many have symptoms that do not sufficiently respond to PPI therapy. | Nora B Zschau Jane M Andrews Richard H Holloway Mark N Schoeman Kylie Lange William CE Tam Gerald J Holtmann | 2013 | World Journal of Gastroenterology2013，19，16： | 2 |
| 15 | Development of theory of mind and executive control 显示文摘 | Pemer J Lang B | 1999 | Trends Cogn Sci1999，3，9： | 1 |
| 16 | CD133,a novel marker for human prostatic epithelial stem cells显示文摘 | Richardson G D Robson C N Lang S H Neal D E Maitland N J Collins A T | 2004 | J Cell Sci2004，117，16： | 1 |
| 17 | gibberellin biosynthesis and the regulation of plant development显示文摘 | Pimenta Lange M J Lange T | 2006 | Plant Biology2006，，3： | 1 |
| 18 | Translating biomolecular recognition into nanomechanics显示文摘 | Fritz J Bailer M K Lang H P | 2000 | Science2000，288，： | 1 |
| 19 | Interdigitated Stripline Quadrature Hybrid (Correspondence)显示文摘 | | 1969 | IEEE Microwave Theroy and Techniques1969，12，： | 1 |
| 20 | The outcomes and costs of acute myeloid leukemia among the elderly 显示文摘 | Menzin J Lang K Earle CC | 2002 | Arch Inter Med2002，162，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员